A citation-based method for searching scientific literature

Kristin Bergethon, Alice T Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M Lovly, Nerina T McDonald, Pierre P Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang, Eugene J Mark, Julie M Batten, Haiquan Chen, Keith D Wilner, Eunice L Kwak, Jeffrey W Clark, David P Carbone, Hongbin Ji, Jeffrey A Engelman, Mari Mino-Kenudson, William Pao, A John Iafrate. J Clin Oncol 2012
Times Cited: 988



Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa, Robert C Doebele, Long Phi Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S Martin Shreeve, Lesley M Tye, James G Christensen, Keith D Wilner, Jeffrey W Clark, A John Iafrate. N Engl J Med 2014
Times Cited: 1095




List of shared articles



Times cited

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors.
Zong-Jun Xia, Yin-Chun Ji, De-Qiao Sun, Xia Peng, Ying-Lei Gao, Yan-Fen Fang, Xing-Dong Zhao, Wei-Bo Wang, Jian Ding, Mei-Yu Geng,[...]. Acta Pharmacol Sin 2021
1

Systemic Therapy for Mutation-Driven NSCLC.
Lova Sun, Melina E Marmarelis, Corey J Langer. Semin Radiat Oncol 2021
0

Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting.
Zhenfang Du, Benjamin P Brown, Soyeon Kim, Donna Ferguson, Dean C Pavlick, Gowtham Jayakumaran, Ryma Benayed, Jean-Nicolas Gallant, Yun-Kai Zhang, Yingjun Yan,[...]. Nat Commun 2021
5


A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies.
Sarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, Wendy Xiong, Li Xu, Rosa Mostorino, Vivek Subbiah, Nizar Tannir, Siqing Fu, Aung Naing,[...]. Onco Targets Ther 2021
1

Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper.
Fernando Barata, Carlos Aguiar, Tiago Reis Marques, José Bravo Marques, Venceslau Hespanhol. Drug Saf 2021
0

Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
Carol C Cheung, Adam C Smith, Roula Albadine, Gilbert Bigras, Anna Bojarski, Christian Couture, Jean-Claude Cutz, Weei-Yuan Huang, Diana Ionescu, Doha Itani,[...]. Lung Cancer 2021
1

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou,[...]. BMC Med 2021
0

Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission.
Mario González-Sales, Nassim Djebli, Georgina Meneses-Lorente, Vincent Buchheit, Guillaume Bonnefois, Pierre-Olivier Tremblay, Nicolas Frey, François Mercier. Cancer Chemother Pharmacol 2021
0

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
Noura J Choudhury, Jaime L Schneider, Tejas Patil, Viola W Zhu, Debra A Goldman, Soo-Ryum Yang, Christina J Falcon, Andrew Do, Yunan Nie, Andrew J Plodkowski,[...]. JTO Clin Res Rep 2021
0

Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer.
Karim Amrane, Luca Campedel, Coline Le Meur, Ronan Abgral, Dris Kharroubi, Jacques Cadranel. Front Med (Lausanne) 2021
0

Turning liabilities into opportunities: Off-target based drug repurposing in cancer.
Vinayak Palve, Yi Liao, Lily L Remsing Rix, Uwe Rix. Semin Cancer Biol 2021
7

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
18



Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients.
Lázaro Antonio Campanha Novaes, Luciane Sussuchi da Silva, Pedro De Marchi, Rodrigo de Oliveira Cavagna, Flavia Escremim de Paula, Maicon Fernando Zanon, Adriane Feijó Evangelista, Eduardo Caetano Albino da Silva, Vinícius Duval da Silva, Letícia Ferro Leal,[...]. Transl Lung Cancer Res 2021
1

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
0

Proteomic analysis of tyrosine phosphorylation induced by exogenous expression of oncogenic kinase fusions identified in lung adenocarcinoma.
Sebastian A Wagner, Pawel P Szczesniak, Andrea Voigt, Justus F Gräf, Petra Beli. Proteomics 2021
0

Updates in the molecular pathology of non-small cell lung cancer.
Elizabeth Paver, Sandra O'Toole, Xin Min Cheng, Annabelle Mahar, Wendy A Cooper. Semin Diagn Pathol 2021
0

A novel CD74-ROS1 gene fusion in a patient with inflammatory breast cancer: a case report.
Huiyu Hu, Nianhua Ding, Haiyan Zhou, Shouman Wang, Lili Tang, Zhi Xiao. J Med Case Rep 2021
0


Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
0

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
2


Immunotherapy in oncogene addicted non-small cell lung cancer.
Luke McLean, Jose Luis Leal, Benjamin J Solomon, Thomas John. Transl Lung Cancer Res 2021
0

A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Mizuha Haraguchi Hashiguchi, Takashi Sato, Rinako Watanabe, Junko Kagyo, Tomohiko Matsuzaki, Hideharu Domoto, Terufumi Kato, Yoshiro Nakahara, Tomoyuki Yokose, Yukihiko Hiroshima,[...]. Thorac Cancer 2021
1

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy.
Olga Rodak, Manuel David Peris-Díaz, Mateusz Olbromski, Marzenna Podhorska-Okołów, Piotr Dzięgiel. Cancers (Basel) 2021
1

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.
Richard S P Huang, Derek Smith, Catherine H Le, Wen-Wei Liu, Ellen Ordinario, Chitra Manohar, Michael Lee, Jaya Rajamani, Huan Truong, Jing Li,[...]. Arch Pathol Lab Med 2020
9

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Subba R Digumarthy, Dexter P Mendoza, Jessica J Lin, Tianqi Chen, Marguerite M Rooney, Emily Chin, Lecia V Sequist, Jochen K Lennerz, Justin F Gainor, Alice T Shaw. Clin Lung Cancer 2020
12

Precision Management of Advanced Non-Small Cell Lung Cancer.
Ching-Yao Yang, James Chih-Hsin Yang, Pan-Chyr Yang. Annu Rev Med 2020
24

Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
Danielle Cohen, Liesbeth M Hondelink, Nienke Solleveld-Westerink, Sandra M Uljee, Dina Ruano, Anne-Marie Cleton-Jansen, Jan H von der Thüsen, S Rajen S Ramai, Pieter E Postmus, Jacob F Graadt van Roggen,[...]. J Thorac Oncol 2020
21




Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Andrea Sartore-Bianchi, Elio Gregory Pizzutilo, Giovanna Marrapese, Federica Tosi, Giulio Cerea, Salvatore Siena. Expert Rev Anticancer Ther 2020
9

Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis.
Fränce Hardtstock, David Myers, Tracy Li, Diana Cizova, Ulf Maywald, Thomas Wilke, Frank Griesinger. BMC Cancer 2020
3

Intratumor Heterogeneity in Early Lung Adenocarcinoma.
Maria-Fernanda Senosain, Pierre P Massion. Front Oncol 2020
8

Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells.
Abdulaziz B Hamid, Ruben C Petreaca. Cancers (Basel) 2020
1